



Dkt. 04010

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Group Art Unit: 1616

MICHEL LANQUETIN et al Examiner: S. Qazi

Serial No.: 09/284,147 MAIL STOP AF

Filed: March 17, 1999

For: HORMONAL COMPOSITION CONSISTING OF AN OESTROGEN
COMPOUND AND OF A PROGESTATIONAL COMPOUND

AMENDMENT

Honorable Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed September 29,
2003, please amend the above-identified application as
follows:

Amendments to the Claims are reflected in the listing of
claims which begins on page 2 of this paper.

Remarks begin on page 3 of this paper.

LAW OFFICES
DENNISON, SCHULTZ, DOUGHERTY & MACDONALD
SUITE 105
1727 KING STREET
ALEXANDRIA, VIRGINIA 22314-2700
703 837-9600

IN THE CLAIMS:

Please cancel claims 30 and 37-40 without prejudice or disclaimer of the subject matter thereof.

The following is a complete listing of claims in this application.

Claims 1-24 (canceled). /

2 28. (previously presented) The method of claim 34 wherein the estrogen is an ester of estradiol.

Claims 26-27 (canceled). /

3 28. (previously presented) The method of claim 34 wherein the composition contains 1.5 mg of free estradiol by daily dose.

4 29. (previously presented) The method of claim 34 wherein the composition contains 2 mg of ester of estradiol by daily dose.

Claims 30-32 (canceled). /

5 33. (previously presented) The method of claim 34 wherein the composition contains 2.5 mg of nomegestrol acetate by daily dose.

1 34. (currently amended) A method of treating estrogenic deficiencies in post menopausal women while further avoiding the appearance of osteoporosis and withdrawal bleeding, comprising continuously without interruption administering to said women a composition containing from 0.5 to 3 mg of an estrogen selected from the group consisting of free or and esterified estradiol and 1.5 to 3.75 mg of nomegestrol acetate by daily dose.

Claim 35 (cancelled) /

6 36. (previously presented) The method of claim 34 wherein the composition is administered orally.

Claims 37-40 (canceled).